Abstract 88P
Background
The WHO Model List of Essential Medicines (EML) serves as guidance for the development of national lists of essential medicines. Since ipilimumab was first approved in 2011, immune checkpoint inhibitors (ICI) have changed the oncologic treatment landscape, leading to significant survival advantages. However, except for malignant melanoma, repeated EML applications of ICIs were unsuccessful and global access remains limited. This study was part of a WHO EML application for the therapeutic class of ICIs in the palliative first-line treatment setting of adult cancers and aims to provide a prioritization framework to select ICIs and indications with the highest potential for EML inclusion.
Methods
After drafting a goal-directed, sequential prioritization plan, the European Medicines Agency’s (EMA) drug database was searched systematically for approved ICI and treatment indications. Next, based on the potential population reach and availability of high-level evidence, ICI-containing treatments approved for the palliative first-line setting were reviewed. Lastly, ESMO-Magnitude of Clinical Benefit Scale (MCBS) scorecards were examined to identify therapeutic indications with a score of 4 or 5, denoting a substantial clinical benefit. ESMO experts will review top-ranked regimens and cancers to complement the evidence about efficacy and harms, judge feasibility and accessibility, and discuss controversial additions.
Results
The EMA drug database search yielded 11 ICIs with 76 different approvals for 21 cancer types and subtypes. Of these, 44 approvals were in the palliative first-line setting. Evaluation against ESMO-MCBS scorecards led to the inclusion of 29 approvals for further evaluation and analysis. Briefing documents for selected cancers and ICIs, with input from ESMO experts, will enhance the transparency and completeness of the EML application to support the WHO Expert committee's selection.
Conclusions
Our research demonstrates the feasibility of using the ESMO-MCBS as part of a framework to identify and prioritise promising ICI-containing treatment regimens for WHO EML application. Therefore, further exploration of the framework as part of the WHO EML application process is warranted.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
185P - Characterizing the metabolic reprogramming of mutant ß-catenin in hepatocellular carcinoma
Presenter: Nathalie Wong
Session: Poster Display session
Resources:
Abstract
186P - Unveil and overcome PD(L)1 antibody resistance via functional genomics and clinical derived biopsies
Presenter: BIN XIE
Session: Poster Display session
Resources:
Abstract
187P - Single-cell RNA sequencing elucidates the role of intercommunication between epithelial cells, immune cells, and fibroblasts in high-grade serous ovarian cancer
Presenter: Xiaoting Zhao
Session: Poster Display session
Resources:
Abstract
188P - Single-cell and spatial transcriptomics delineate the microstructure and immune landscape of intrahepatic cholangiocarcinoma in the leading-edge area
Presenter: Zuyin li
Session: Poster Display session
Resources:
Abstract
189P - Image-guided labeling of live cells in tertiary lymphoid structures for single-cell transcriptomics
Presenter: Mengrui Cao
Session: Poster Display session
Resources:
Abstract
190P - Ex vivo modeling of precision immuno-oncology responses in lung cancer
Presenter: Bassel Alsaed
Session: Poster Display session
Resources:
Abstract
191P - Patient-derived 3D-bioprinted tumours as a relevant and innovative tool for immunotherapeutic testing.
Presenter: Kamila Pawlicka
Session: Poster Display session
Resources:
Abstract
192P - A new neuroendocrine model and in vitro effect of melatonin and serotonin on the PD-L1 ligand and its immunomodulatory action
Presenter: Dulce Caraveo Gutiérrez
Session: Poster Display session
Resources:
Abstract
193P - Humanized mice applying CD47; Prkcd; IL2rg triple KO mice exhibit enhanced human immune cell engraftment and reduced GvHD symptoms
Presenter: Seung-Ho Heo
Session: Poster Display session
Resources:
Abstract
194P - The impact of BTK inhibitors on ?d T cell fitness: Lesson for immunotherapy
Presenter: Adam Michalski
Session: Poster Display session
Resources:
Abstract